¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

¼¼°èÀ¯¹æ¾ÏÇмú´ëȸ 2024 ¹× Çѱ¹À¯¹æ¾ÏÇмú´ëȸ (GBCC 2024) (1ÀÏÂ÷) : 2024-04-25

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

¼¼°èÀ¯¹æ¾ÏÇмú´ëȸ 2024 ¹× Çѱ¹À¯¹æ¾ÏÇмú´ëȸ (GBCC 2024) (1ÀÏÂ÷) : 2024-04-25
±³À°ÀÏÀÚ : 2024-04-25
±³À°Àå¼Ò : ¿öÄ¿Èú È£ÅÚ ¼­¿ï (ÁöÇÏ2Ãþ, ÁöÇÏ1Ãþ, 1Ãþ, 4Ãþ)

±³À°ÁÖÁ¦ : ¼¼°èÀ¯¹æ¾ÏÇмú´ëȸ 2024 ¹× Çѱ¹À¯¹æ¾ÏÇмú´ëȸ (GBCC 2024) (1ÀÏÂ÷)

ÁÖÃÖ±â°ü : Çѱ¹À¯¹æ¾ÏÇÐȸ
´ã´çÀÚ : À̽ÿÂ
¿¬¶ôó : 02-3452-7291  

À̸ÞÀÏ : gbcc@intercom.co.kr

±³À°Á¾·ù : ¿Ü°ú, ¼ºÇü¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ÀÇ»çÇÐ, ¿¹¹æÀÇÇÐ, ÀÇÇб³À°, ÀÇ·á°æ¿µ

Âü¼®¿¹»óÀÎ : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 30 ½Ã°£ 18ºÐ

¼¼ºÎ¼ö°­·á : 800,000¿ø  

ºñ°í [Á¶±âµî·Ï(2023.11.01-2024.02.01)]Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSȸ¿ø) 400,000Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSºñȸ¿ø) 500,000Àü°øÀÇ/°£È£»ç/¿¬±¸¿ø/±ºÀÇ°ü/Çлý 150,000[»çÀüµî·Ï(2024.02.02-2024.04.05)]Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSȸ¿ø) 480,000Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSºñȸ¿ø) 600,000Àü°øÀÇ/°£È£»ç/¿¬±¸¿ø/±ºÀÇ°ü/Çлý 200,000[ÇöÀåµî·Ï(2024.04.25-2024.04.27)]Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSȸ¿ø) 640,000Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSºñȸ¿ø) 800,000Àü°øÀÇ/°£È£»ç/¿¬±¸¿ø/±ºÀÇ°ü/Çлý 250,000*http://gbcc.kr/Contents.asp?LoadPage=Instruction&Tap=B


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±âŸ 04¿ù 25ÀÏ Room 1 (Vista 1+2) 08:45~09:00 Opening Ceremony ()

±³À°½Ã°£ 04¿ù 25ÀÏ Room 1 (Vista 1+2) 09:00~09:25 [Symposium 1: States-of-Art: Personalized Surgery in Breast Cancer] Re-thinking Surgical Management in Ipsilateral Breast Tumor Recurrence Sung Gwe Ahn(Gangnam Severance Hospital, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 1 (Vista 1+2) 09:25~09:50 [Symposium 1: States-of-Art: Personalized Surgery in Breast Cancer] Tailored Axillary Surgery in Axillary Node-Positive Breast Cancer Andrea Barrio(Memorial Sloan Kettering Cancer Center, U.S.A.)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 1 (Vista 1+2) 09:50~10:15 [Symposium 1: States-of-Art: Personalized Surgery in Breast Cancer] Omission of Breast Surgery in Patients with Exceptional Response to Neoadjuvant Systemic Therapy Tomomi Fujisawa(Gunma Prefectural Cancer Center, Japan)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Room 2 (Grand 1)) 09:00~09:20 [Panel Discussion 1:Optimizing Treatment Sequence After CDK4/6 Inhibitors] Resistance Mechanism of CDK4/6 Inhibitor: Primary or Acquired Dennis Slamon(Univ. of California, Los Angeles, U.S.A.)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Room 2 (Grand 1)) 09:20~09:40 [Panel Discussion 1:Optimizing Treatment Sequence After CDK4/6 Inhibitors] What Is the Optimal Treatment Strategy After the First Line CDK4/6 Inhibitor? Yoon-Sim Yap(National Cancer Centre Singapore, Singapore)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Room 2 (Grand 1)) 09:40~10:00 [Panel Discussion 1:Optimizing Treatment Sequence After CDK4/6 Inhibitors] Antibody Drug Conjugate for HR+HER2- MBC In Hae Park(Korea Univ. Guro Hospital, Korea)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Room 2 (Grand 1)) 10:00~10:15 [Panel Discussion 1:Optimizing Treatment Sequence After CDK4/6 Inhibitors] Discussion ()

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 09:00~09:25 [Symposium 2: Artificial Intelligence: Past, Present and Future] Practical Considerations and the Implementation of AI Tools for Breast Cancer Risk Prediction Thijs Kooi(Lunit Inc., Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 09:25~09:50 [Symposium 2: Artificial Intelligence: Past, Present and Future] Artificial Intelligence in Real-World Experiences: Perspectives of Radiologists Won Hwa Kim(Kyungpook National Univ. Hospital, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 09:50~10:15 [Symposium 2: Artificial Intelligence: Past, Present and Future] Artificial Intelligence in Breast Pathology: Current Landscape and Future Prospects Miseon Lee(The Catholic Univ. of Korea, Seoul St. Mary)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 09:00~09:25 [IERBS 2024 1: Current Status and Issues for Robotic and Endoscopic NSM] Patients Selection of Robotic and Endoscopic NSM for Beginners Sae Byul Lee(Univ. of Ulsan College of Medicine, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 09:25~09:50 [IERBS 2024 1: Current Status and Issues for Robotic and Endoscopic NSM] Ongoing Studies of Robotic or Endoscopic NSM Chi Wei Mok(Changi General Hospital, Singhealth Duke-NUS Breast Centre, Singapore)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 09:50~10:15 [IERBS 2024 1: Current Status and Issues for Robotic and Endoscopic NSM] Current Application of Robotic and Endoscopic NSM for High Risk of Breast Cancer Patients Deborah Farr(UT Southwestern Harold C. Simmons Cancer Center, U.S.A.)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 09:00~09:20 [GBCC-TBCS Joint Session: Asian Premenopausal Women with Breast Cancer] Epidemiology and Characteristics of Young Patients with Breast Cancer in Asian Countries Ching-Hung Lin(National Taiwan Univ. Hospital, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 09:20~09:40 [GBCC-TBCS Joint Session: Asian Premenopausal Women with Breast Cancer] Surgical Management of Breast Cancer in Young Asian Patients and Perspectives in Clinical Research Jai Min Ryu(Samsung Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 09:40~10:00 [GBCC-TBCS Joint Session: Asian Premenopausal Women with Breast Cancer] Medical Management of Breast Cancer in Young Asian Patients and Perspectives in Clinical Research Chi-Cheng Huang(Taipei Veterans General Hospital, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 10:00~10:15 [GBCC-TBCS Joint Session: Asian Premenopausal Women with Breast Cancer] Discussion ()

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 09:00~09:08 [Oral Presentation 1] EFFECT OF BRCA 1/2 MUTATION ON THE LONG-TERM ONCOLOGIC OUTCOME OF BREAST CANCER PATIENTS WHO UNDERWENT BREAST-CONSERVING SURGERY (KOREA-BSG 06) Chihwan Cha(Hanyang Univ. College of Medicine, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 09:08~09:16 [Oral Presentation 1] THE PERFORMANCE OF MOBILE UNITS VERSUS HOSPITAL UNITS IN NATIONAL BREAST CANCER SCREENING PROGRAM IN TAIWAN, 2010-2020 Pham Thao Vy Vu(Taipei Medical University, Taiwan)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 09:16~09:24 [Oral Presentation 1] LOW DOSE BREAST CT USING DEEP LEARNING-BASED TECHNIQUE FOR NOISE REDUCTION Myoung Kyoung Kim(Samsung Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 09:24~09:32 [Oral Presentation 1] BREAST CANCER RISK GENES ANALYSIS WITH WHOLE GENOME SEQUENCING WITH BRCA 1/2 MUTATION-NEGATIVE BREAST CANCER IN SAMSUNG MEDICAL CENTER Youngji Kwak(Samsung Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 09:32~09:40 [Oral Presentation 1] PREOPERATIVE IMPACTING FACTORS ON TUMOR GROWTH DURING THE WAIT TIME FOR BREAST CANCER SURGERY Ikbeom Shin(Seoul National Univ., Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 09:40~09:48 [Oral Presentation 1] A COHORT ON HEALTH-RELATED QUALITY OF LIFE AND PSYCHOLOGICAL HEALTH OF LONG-TERM BREAST CANCER SURVIVORS IN KOREA Thi Xuan Mai Tran(Hanyang University College of Medicine, Vietnam)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 09:48~09:56 [Oral Presentation 1] A RANDOMIZED CONTROLLED TRIAL INVESTIGATING CLINICAL EFFICACY OF MHEALTH APPS IN BREAST CANCER SURVIVORS Young-Jin Lee(ASAN Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 09:56~10:04 [Oral Presentation 1] ESTABLISHING AND ADVANCED PRACTICE NURSE (APN)-LED BREAST CANCER SURVIVORSHIP CLINIC AT THE NATIONAL UNIVERSITY CANCER INSTITUTE (NCIS): A YEAR Litang Chen(National University Cancer Institute, Singapore, Singapore)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 10:04~10:12 [Oral Presentation 1] SUMMARIZING PATIENT MEDICAL RECORDS FOR ACCURATE PHYSICIAN COMMUNICATION: A COMPARISON OF HUMAN VS. AI-BASED APPROACHES Jijung Jung(Seoul National Univ., Korea)

ÈÞ½Ä 04¿ù 25ÀÏ 10:15~10:30 Break ()

±³À°½Ã°£ 04¿ù 25ÀÏ Room 1 (Vista 1+2) 10:30~10:55 [Symposium 3: The New Frontier of Endocrine Treatment for Breast Cancer] Oral SERDs and Novel Endocrine Therapy Agents Gun Min Kim(Yonsei Univ. College of Medicine, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 1 (Vista 1+2) 10:55~11:20 [Symposium 3: The New Frontier of Endocrine Treatment for Breast Cancer] Targeting PI3K-AKT-mTOR Pathway in HR+ Breast Cancer Yen-Shen Lu(National Taiwan Univ. Hospital, Taiwan)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 1 (Vista 1+2) 11:20~11:45 [Symposium 3: The New Frontier of Endocrine Treatment for Breast Cancer] New Targets in Hormone Receptor Positive Breast Cancer Yeon Hee Park(Samsung Medical Center, Korea)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 10:30~10:50 [Panel Discussion 2:Surgical Controversies Before and After Neoadjuvant Chemotherapy in the Era of Targeted Therapy] Need to Complete Removal of Residual Microcalcifications? - In Case Highly Suggestive of Clinical pCR in MRI and with Residual Diffuse Microcalcification in Mammogram Tari King(Dana-Farber Brigham Cancer Center, U.S.A.)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 10:50~11:10 [Panel Discussion 2:Surgical Controversies Before and After Neoadjuvant Chemotherapy in the Era of Targeted Therapy] Inflammatory Breast Cancer Following Good Response to Neoadjuvant Therapy: No Longer an Absolute Contraindication for Breast Conservation or Skin-Sparing Mastectomy? - Does Initial Extent or Severity Matter? Stephanie M. Wong(Jewish General Hospital Segal Cancer Centre, Canada)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 11:10~11:30 [Panel Discussion 2:Surgical Controversies Before and After Neoadjuvant Chemotherapy in the Era of Targeted Therapy] Young Age Breast Cancer with cT1-3Nx, Low Grade, ER+ Tumor - Upfront Surgery or Neoadjuvant Chemotherapy? Hideko Yamauchi(Univ. of Hawai)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 11:30~11:45 [Panel Discussion 2:Surgical Controversies Before and After Neoadjuvant Chemotherapy in the Era of Targeted Therapy] Discussion ()

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 10:30~10:55 [Education Session 1: What Radiologists Should Know for Optimal Interpretation in Patients Treated with NAC] Synergy from Surgical Viewpoint: A Holistic Imaging Interpretation with Intraoperative Experience Joon Jeong(Gangnam Severance Hospital, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 10:55~11:20 [Education Session 1: What Radiologists Should Know for Optimal Interpretation in Patients Treated with NAC] Synergy from Oncological Viewpoint: Exploring Current Trends and Principles of Chemotherapy Jae-Joon Kim(Pusan National Univ. Yangsan Hospital, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 11:20~11:45 [Education Session 1: What Radiologists Should Know for Optimal Interpretation in Patients Treated with NAC] Contemporary Imaging Insights and Interpretation Considerations for Patients Undergoing Neoadjuvant Systemic Therapy Kazunori Kubota(Dokkyo Medical Univ. Saitama Medical Center, Japan)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 10:30~10:55 [IERBS 2024 2: Initiation and Troubleshooting of Robotic and Endoscopic NSM] Implication of Dry and Cadaveric Skill Labs for Robotic and Endoscopic NSM Jeffrey Johnson(Mayo Clinic, U.S.A.)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 10:55~11:20 [IERBS 2024 2: Initiation and Troubleshooting of Robotic and Endoscopic NSM] Robotic and Endoscopic NSM in Large & Ptotic Patients Wen-Ling Kuo(Chang Gung Memorial Hospital, Taiwan)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 11:20~11:45 [IERBS 2024 2: Initiation and Troubleshooting of Robotic and Endoscopic NSM] Managing Postop-Complications of Robotic and Endoscopic NSM Compared to Open NSM Eisuke Fukuma(Kameda Medical Center, Japan)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 10:30~10:55 [Special Session: GBCC-BIG25: Exploring the Significance of BIG in Asia and Opportunities for Collaboration] Asia in Breast Study Group (BIG) David Cameron(The Univ.of Edinburgh, United Kingdom)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 10:55~11:20 [Special Session: GBCC-BIG25: Exploring the Significance of BIG in Asia and Opportunities for Collaboration] Collaboration Experience with BIG Sung-Bae Kim(ASAN Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 11:20~11:45 [Special Session: GBCC-BIG25: Exploring the Significance of BIG in Asia and Opportunities for Collaboration] BIG Patient Partnership Initiative: Developing Clinical Trials through Patient Partnership Carmela Caballero(Breast International Group, Belgium)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 10:30~10:38 [Oral Presentation 2] EVALUATION OF COMPLIANCE TO ADJUVANT ENDOCRINE THERAPY (ET) IN HORMONE RECEPTOR-POSITIVE (HR+) EARLY BREAST CANCER IN YOUNG WOMEN (Y-EBC) FROM A TERTIARY CARE CANCER CENTER IN INDIA Jyoti Bajpai(Tata Memorial Center, India)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 10:38~10:46 [Oral Presentation 2] THE IMPACT OF ADDING GONADOTROPHIN-RELEASING HORMONE AGONIST TO ADJUVANT ENDOCRINE THERAPY IN PREMENOPAUSAL WITH SMALL NODE NEGATIVE HORMONE-POSITIVE BREAST CANCER ON SURVIVAL AND DISEASE RECURRENCE Sarah Alsafi(Al Adan Hospital, Ministry of Health, Kuwait, Kuwait)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 10:46~10:54 [Oral Presentation 2] COMPARATIVE ONCOLOGICAL OUTCOMES OF PREMENOPAUSAL WOMEN WITH OVARIAN FUNCTION SUPPRESSION AND POSTMENOPAUSAL WOMEN IN ER+/HER2- BREAST CANCER Jijung Jung(Seoul National Univ., Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 10:54~11:02 [Oral Presentation 2] A PHASE III TRIAL COMPARING T-DM1 WITH HPD IN OLDER PATIENTS WITH METASTATIC HER2-POSITIVE BREAST CANCER Akihiko Shimomura(National Center for Global Health and Medicine, Japan)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 11:02~11:10 [Oral Presentation 2] DYNAMIC IMPACT OF CLINICOPATHOLOGICAL FEATURES AND TREATMENTS ON SURVIVAL IN PATIENTS WITH SURGICAL BREAST CANCER: A RETROSPECTIVE POPULATION-BASED COHORT STUDY Maoshan Chen(Suining Central Hospital, China)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 11:10~11:18 [Oral Presentation 2] NO SURVIVAL DIFFERENCE BETWEEN INITIAL INFILTRATING BREAST CANCERS EITHER DEVELOPING METACHRONOUS CONTRALATERAL BREAST CANCER OR NOT Byeongkwan Park(The Catholic Univ. of Korea, St. Vincent)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 11:18~11:26 [Oral Presentation 2] SOCIODEMOGRAPHIC, CLINICAL, AND BIOMARKER PREDICTORS OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN PATIENTS WITH BREAST CANCER: A CLASSIFICATION AND REGRESSION TREE (CART) ANALYSIS Juan Adrian Wiranata(Faculty Of Medicine, Public Health And Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 11:26~11:34 [Oral Presentation 2] PROGNOSTIC ANALYSIS ACCORDING TO ADJUVANT CHEMOTHERAPY AND ANTI-HER2 THERAPY FOLLOWING SURGERY IN T1A/B HER2-POSITIVE BREAST CANCER Woochan Park(Seoul National Univ. Hospital, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 11:34~11:42 [Oral Presentation 2] CLINICAL OUTCOMES AND PROGNOSTIC FACTORS OF PATIENTS WITH EARLY METAPLASTIC BREAST CANCER Dakyung Seo(Univ. of Ulsan College of Medicine, Korea)

ÈÞ½Ä 04¿ù 25ÀÏ 11:45~12:00 Break ()

±³À°½Ã°£ 04¿ù 25ÀÏ Room 1 (Vista 1+2) 12:00~12:45 [Plenary Lecture 1] Inhibition of the CDK4/6/Rb/Cyclind Pathway in ER+/HER2- Breast Cancer Dennis Slamon(Univ. of California, Los Angeles, U.S.A.)

ÈÞ½Ä 04¿ù 25ÀÏ 12:45~13:00 Break ()

±³À°½Ã°£ 04¿ù 25ÀÏ Room 1 (Vista 1+2) 13:00~13:45 [Satellite Symposium 1: Daiichi-Sankyo & AstraZeneca] ENHERTU, Unlocking New Frontiers in mBC Treatment: From HER2-Positive to HER2-Low Jieun Lee(The Catholic Univ. of Korea, Seoul St. Mary)

ÈÞ½Ä 04¿ù 25ÀÏ 13:45~14:00 Break ()

±³À°½Ã°£ 04¿ù 25ÀÏ Room 1 (Vista 1+2) 14:00~14:45 [Plenary Lecture 2] Evidence-Based Breast Radiotherapy: Canadian Experiences Timothy Whelan(McMaster Univ., Canada)

Åä·Ð 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 14:00~14:15 [IERBS 2024 3: Debate: Does Robot-Assisted NSM Have a Role Ou] Pros Antonio Toesca(Candiolo Cancer Institute, Italy)

Åä·Ð 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 14:15~14:30 [IERBS 2024 3: Debate: Does Robot-Assisted NSM Have a Role Ou] Cons Andrea Barrio(Memorial Sloan Kettering Cancer Center, U.S.A.)

Åä·Ð 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 14:30~14:45 [IERBS 2024 3: Debate: Does Robot-Assisted NSM Have a Role Ou] Q&A ()

ÈÞ½Ä 04¿ù 25ÀÏ 14:45~15:00 Break ()

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 15:00~15:20 [Panel Discussion 3: Beyond Borders: Breaking Barriers of Subtypes] Tumor Agnostic Trials Across Subtypes in Metastatic Breast Cancer Giuseppe Curigliano(European Institute of Oncology and Univ. of Milano, Italy)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 15:20~15:40 [Panel Discussion 3: Beyond Borders: Breaking Barriers of Subtypes] Beyond the Guidelines: Clinical Investigator Perspectives on the Management of HER2-Low Breast Cancer Janice Tsang(The Univ. of Hong Kong, Hong Kong )

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 15:40~16:00 [Panel Discussion 3: Beyond Borders: Breaking Barriers of Subtypes] Identifying Biological Entity That Is Sensitive to Immune Checkpoint Inhibitors Hee Kyung Ahn(Gachon Univ. Gil Medical Center, Korea)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 16:00~16:15 [Panel Discussion 3: Beyond Borders: Breaking Barriers of Subtypes] Discussion ()

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 15:00~15:25 [Education Session 2: Biomarkers Guided Treatment in ER+HER2- Breast Cancer] Liquid Biopsies Guided Treatment in ER+HER2- Breast Cancer Jisun Kim(ASAN Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 15:25~15:50 [Education Session 2: Biomarkers Guided Treatment in ER+HER2- Breast Cancer] Multigene Assays Based Decision for Extended Endocrine Therapy Masakazu Toi(Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Japan)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 15:50~16:15 [Education Session 2: Biomarkers Guided Treatment in ER+HER2- Breast Cancer] Biomarkers for Neoadjuvant Endocrine Therapy Hyun Jo Youn(Jeonbuk National Univ., Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 15:00~15:25 [IERBS 2024 4: PS Session] Robot-Assisted Breast Reconstruction Benjamin Sarfati(Institut Gustave Roussy, France)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 15:25~15:50 [IERBS 2024 4: PS Session] Robot-Assisted Breast Reconstruction Dong-Won Lee(Yonsei Univ., Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 15:50~16:15 [IERBS 2024 4: PS Session] Autologous Breast Reconstruction - Japanese Trend and Our Strategy Hiroki Mori(Tokyo Medical and Dental Univ., Japan)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 15:00~15:25 [GBCC-SSO Joint Session: Where We Are and Where We Go] Sentinel Lymph Node Biopsy in Upfront Surgery Tari King(Dana-Farber Brigham Cancer Center, U.S.A.)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 15:25~15:50 [GBCC-SSO Joint Session: Where We Are and Where We Go] Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy Jeong Eon Lee(Samsung Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 15:50~16:15 [GBCC-SSO Joint Session: Where We Are and Where We Go] Sentinel Lymph Node Biopsy in Ipsilateral Breast Tumor Recurrence Ko Un Clara Park(Dana-Farber Brigham Cancer Center, U.S.A.)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 15:00~15:08 [Oral Presentation 3] INTRAOPERATIVE SUPINE MRI FOR BREAST CONSERVING THERAPY: FINAL RESULTS OF AMIGO (ADVANCED MULTI-MODALITY IMAGE GUIDED OPERATING SUITE) PHASE II CLINICAL TRIAL Leah Kim(Yale University School of Medicine, U.S.A.)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 15:08~15:16 [Oral Presentation 3] THE OPTIMAL TIMING OF BREAST CANCER SURGERY AFTER COVID-19 INFECTION: AN OBSERVATIONAL STUDY Zhao Bi(Shandong Cancer Hospital & Institute, China)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 15:16~15:24 [Oral Presentation 3] A COMPARATIVE STUDY OF LOCAL RECURRENCE AND PROGNOSIS OF MULTIPLE BREAST CONSERVING SURGERY VERSUS MASTECTOMY IN PATIENTS WITH MULTIPLE IPSILATERAL BREAST CANCER Asuka Kawabata(St. Luke)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 15:24~15:32 [Oral Presentation 3] MINIMALLY INVASIVE BIOPSY TECHNIQUE PREDICTING BREAST PATHOLOGICAL COMPLETE RESPONS AFTER NEOADJUVANT CHEMOTHERAPY FOR BREAST CANCER Zhiqiang Shi(Shandong Cancer Hospital & Institute, China)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 15:32~15:40 [Oral Presentation 3] IMPACT OF UNILATERAL MASTECTOMY WITH OR WITHOUT IMMEDIATE BREAST RECONSTRUCTION ON VERTEBRAL ALIGNMENT Jong-Ho Cheun(Seoul National Univ., Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 15:40~15:48 [Oral Presentation 3] TO DISSECT OR NOT TO DISSECT? PREDICTING ¡Ã 4 AXILLARY LYMPH NODE METASTASES IN EARLY-STAGE BREAST CANCER FROM A SURGEON Damiano Gentile(IRCCS Humanitas Research Hospital, Italy)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 15:48~15:56 [Oral Presentation 3] ANALYSIS THE NUMBER OF ADDITIONAL NON-SENTINEL LYMPH NODE METASTASIS WHEN ONLY MICROMETASTASIS WAS DETECTED IN THE SENTINEL LYMPH NODE BIOPSY IN FROZEN SECTION AFTER NEOADJUVANT CHEMOTHERAPY FOLLOWED Dong Seung Shin(Samsung Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 15:56~16:04 [Oral Presentation 3] EVALUATING THE SURVIVAL OUTCOMES IN CN2-3 BREAST CANCER PATIENTS AFTER NEOADJUVANT CHEMOTHERAPY: SENTINEL LYMPH NODE BIOPSY ALONE VS. AXILLARY LYMPH NODE DISSECTION Eunju Shin(ASAN Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 16:04~16:12 [Oral Presentation 3] THE EFFECT OF AXILLARY SURGERY ON THE PROGNOSIS OF IBTR AFTER BCS Jongyeon Yoon(ASAN Medical Center, Korea)

ÈÞ½Ä 04¿ù 25ÀÏ 16:15~16:30 Break ()

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 16:30~16:50 [Panel Discussion 4: Subtype-Based Optimization of Locoregional Treatments for Small Tumors] Treatment Approach in Small HER2+ or TNBC: Upfront Surgery vs Neoadjuvant Chemotherapy? Marios Tasoulis(The Royal Marsden NHS Foundation Trust, United Kingdom)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 16:50~17:10 [Panel Discussion 4: Subtype-Based Optimization of Locoregional Treatments for Small Tumors] Small Luminal a Breast Cancer in Postmenopausal Women: SLNB Omission vs RT Omission? Tadahiko Shien(Okayama Univ. Hospital, Japan)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 17:10~17:30 [Panel Discussion 4: Subtype-Based Optimization of Locoregional Treatments for Small Tumors] Small Luminal a Breast Cancer in Postmenopausal Women: Tailored Approach of Radiotherapy Bum-Sup Jang(Seoul National Univ. Hospital, Korea)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 17:30~17:45 [Panel Discussion 4: Subtype-Based Optimization of Locoregional Treatments for Small Tumors] Discussion ()

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 16:30~16:55 [Education Session 3: The Power of Genomics for Breast Cancer] Technology of Genomic Profiling in Breast Cancer: How to Interpret Genomic Testing In Hye Song(ASAN Medical Cente, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 16:55~17:20 [Education Session 3: The Power of Genomics for Breast Cancer] Tumor vs cfDNA Analysis in Breast Cancer Pedram Razavi(Memorial Sloan Kettering Cancer Center, U.S.A.)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 17:20~17:45 [Education Session 3: The Power of Genomics for Breast Cancer] Actionable Mutations in Breast Cancer: Molecular Insights and Therapeutic Approaches Min Hwan Kim(Yonsei Univ. College of Medicine, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 16:30~17:45 [IERBS 2024 5: Consensus Meeting: Voting Session] Introduction Consensus Meeting of IERBS & Summary of Previous Consensus Meeting of IERBS Hung-Wen Lai(Changhua Christian Hospital, Taiwan)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 16:30~16:55 [ABCN Business Meeting] Sharing Wisdom, Sharing Strength: My Personal Leadership Academy Experience Giuseppe Curigliano(European Institute of Oncology and Univ. of Milano, Italy)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 16:55~17:20 [ABCN Business Meeting] Sharing Wisdom, Sharing Strength: My Personal Leadership Experience for Translational Research Sarat Chandarlapaty(Memorial Sloan Kettering Cancer Center, U.S.A.)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 17:20~17:45 [ABCN Business Meeting] HR+HER2- Clinically Node-Positive Breast Cancer: What To Do First? Sung Gwe Ahn(Gangnam Severance Hospital, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 16:30~16:38 [Oral Presentation 4] CLINICAL AND BIOLOGICAL SIGNIFICANCE OF T-CELL RECEPTOR REPERTOIRE IN PATIENTS WITH BREAST CANCER Chun-Yu Liu(National Yang Ming Chiao Tung University, Taiwan)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 16:38~16:46 [Oral Presentation 4] IMMUNE MARKER EXPRESSION AND PROGNOSIS OF EARLY BREAST CANCER EXPRESSING HER3 Dae-Won Lee(Seoul National Univ. Hospital, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 16:46~16:54 [Oral Presentation 4] INTEGRATING CTDNA TO PREDICT RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY COMBINED WITH IMMUNE THERAPY IN HER2-LOW TRIPLE-NEGATIVE BREAST CANCERS Zhao Bi(Shandong Cancer Hospital & Institute, China)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 16:54~17:02 [Oral Presentation 4] THE IMPACT OF TREATMENT DELAY ON SURVIVAL OF BREAST CANCER PATIENTS: A NATIONWIDE DATA OF SOUTH KOREAN Young-Jin Lee(ASAN Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 17:02~17:10 [Oral Presentation 4] ANALYZING THE RELATIONSHIP BETWEEN MICROBIOME COMPOSITIONS AND TRIPLE-NEGATIVE BREAST CANCER PROGRESSION: MACHINE LEARNING IDENTIFICATION OF MICROBIAL BIOMARKERS AND THERAPEUTIC TARGETS Prihantini Prihantini(Bandung Institute of Technology, Indonesia)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 17:10~17:18 [Oral Presentation 4] CLINICAL-PATHOLOGICAL CHARACTERISTICS ASSOCIATED WITH MULTIGENE ASSAY RISK SCORES, AND PROGNOSTIC IMPACT OF MULTIGENE RISK SCORES IN PATIENTS WITH INVASIVE LOBULAR CARCINOMA Young-Won Lee(ASAN Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 17:18~17:26 [Oral Presentation 4] PREDICTION OF PATHOLOGICAL COMPLETE RESPONSE IN ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER FOLLOWING NEOADJUVANT CHEMOTHERAPY USING THE IHC4 EQUATION Eunhye Kang(Seoul National Univ. Hospital, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 17:26~17:34 [Oral Presentation 4] PROTEOMIC ANALYSIS IDENTIFIES ASSOCIATION OF PERIOSTIN, A MATRICELLULAR PROTEIN, WITH HIGH TUMOR STROMA AND IMMUNE EXCLUSION IN TRIPLE NEGATIVE BREAST CANCER Yeonjin Jeon(ASAN Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 17:34~17:42 [Oral Presentation 4] BREAST CANCER CHARACTERISTICS AND MANAGEMENT IN ELDERLY BRCA MUTATION CARRIERS IN HONG KONG Yuk-Kwan Chang(Queen Mary Hospital, Hong Kong)

±âŸ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 17:45~18:00 KBCS General Assembly ()

½Ä»ç 04¿ù 25ÀÏ Room 1 (Vista 1+2) 18:00~20:00 Welcome Dinner ()

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ¼¼°èÀ¯¹æ¾ÏÇмú´ëȸ 2024 ¹× Çѱ¹À¯¹æ¾ÏÇмú´ëȸ (GBCC 2024) (1ÀÏÂ÷) : 2024-04-25""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑÀÇÇÐÀ¯ÀüÇÐȸ Á¦67Â÷ Ãá°èÇмú´ëȸ : 2024-04-25
´ÙÀ½±Û (¿Â¶óÀÎ) 2024³â Á¦2Â÷ û¼Ò³âÀÇÇÐ Áý´ãȸ(Áö¹æ°£Áúȯ, Çлý°Ç°­°ü¸®) : 2024-04-25
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20613 ´ë±¸ ´ëÇѽºÆ÷Ã÷ÀÇÇÐȸ Sports Medicine Symposium 2024 in Daegu : 2024-06-23 0 0 2024-04-29
20612 ¼­¿ï 2024³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦12Â÷ Clinical Densitometry Course : 2024-06-23 0 1 2024-04-29
20611 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 1Â÷(2ÀÏÂ÷) : 2024-06-22 0 0 2024-04-29
20610 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø (¿Â¶óÀÎ) 6¿ù 21ÀÏ ±Ý¿äÁý´ãȸ(ÀÌ°ü ÁúȯÀÇ Áø´Ü°ú Ä¡·á) : 2024-06-21 0 1 2024-04-29
20609 °æ±â ¾È»ê ¹× ½ÃÈ­Áö¿ª À̺ñÀÎÈÄ°ú Àǻ縦 À§ÇÑ Áý´ãȸ(¾È¸é¸¶ºñ) : 2024-06-21 0 0 2024-04-29
20608 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 1Â÷(1ÀÏÂ÷) : 2024-06-21 0 1 2024-04-29
20607 ¼­¿ï 2024 ´ëÇÑȯ°æõ½ÄÆóÁúȯÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-21 0 0 2024-04-29
20606 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-¿Ü·¡¿¡¼­ °£´ÜÇÏ°Ô ÇÒ ¼ö ÀÖ´Â À½¼ºÄ¡·á : 2024-06-20 0 2 2024-04-29
20605 ´ë±¸ ´ëÇÑ»êºÎÀΰúÇÐȸ ´ë±¸Áöȸ ¿¬¼ö°­Á : 2024-06-20 0 0 2024-04-29
20604 °­¿ø Á¦171ȸ ÇѸ²´ëÇб³Ãáõ¼º½Éº´¿ø ¼ÒÈ­±â ¿¬¼ö±³À° : 2024-06-19 0 0 2024-04-29
20603 °æ±â Á¦16ȸ ±¹¸³¾Ï¼¾ÅÍ ±¹Á¦½ÉÆ÷Áö¾ö : 2024-06-19 0 2 2024-04-29
20602 ¼­¿ï ´ëÇѽÅÀåÇÐȸ APCN & KSN 2024 4ÀÏÂ÷ : 2024-06-16 0 3 2024-04-29
20601 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-06-16 0 1 2024-04-29
20600 ¼­¿ï 2024 Á¦ 2ȸ ¿¬¼¼´ëÇб³ ¼öºÎ ¹× »óÁö ½ÉÆ÷Áö¾ö : 2024-06-16 0 0 2024-04-29
20599 ¼­¿ï ´ëÇÑ»êºÎÀΰú³»ºÐºñÇÐȸ ¿¬¼ö°­Á : 2024 »êºÎÀΰú¹Ì¼º³â¿¬¼ö°­Á : 2024-06-16 0 0 2024-04-29
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷